CYP3A4 기질과 억제제 약물의 병용 고령환자에서 횡문근융해증 부작용 연관성 = Association of Rhabdomyolysis in the Elderly Patients with Combination Therapy of Cytochrome 3A4 Substrates and Inhibitors Based on the Korean Claims Data

다국어 초록 (Multilingual Abstract)

Drug-induced rhabdomyolysis can cause acute kidney injury and rate of polypharmacy is high in the elderly. This study aimed to assess the incidence of rhabdomyolysis with combination therapy of CYP3A4 substrates (S) and inhibitors (I) in the elderly in Korea.
Methods: Patients were selected from the 2017 elderly patient data (the Korean Health Insurance Review and Assessment Service - Aged Population Sample). The list of CYP3A4 S and I was taken from the Indiana university of pharmacy and converted to Korean ATC codes.
Further selection criteria were a medication possession ratio greater than 80%, duration of medication 7 days or longer, and duration of follow-up 3 months or longer. The incidence and odds ratio of rhabdomyolysis with top 50 pairs of the combination of drugs were assessed.
Comparative analysis of the association of rhabdomyolysis with patient characteristics and comorbidities was analyzed using Chi-square test. Logistic regression models were used to analyze the association with rhabdomyolysis for each variable. Results: Rhabdomyolysis was identified in 78 cases in 24,240 patients with 7 days or longer use (DC7), and 19 cases in 3,444 patients with 30 days or longer use (DC30) of CYP3A4 S and I. The comorbidities of severe liver disease and rheumatoid disease had a significant association. Among patients with DC7, the drug pairs (S,I) with significant adjusted odds ratio (aOR) were [clopidogrel, cimetidine] (0.32; 95% CI, 0.10–0.96). Among patients with DC30, the drug pairs with significant aOR were [atorvastatin and fluconazole] (16.13; 95% CI, 2.40–108.36), [alprazolam and amiodarone] (10.74; 95% CI, 1.62–71.38), [zolpidem tartrate and ciprofloxacin] (9.61; 95% CI, 1.38–66.83), [lansoprazole and amiodarone] (7.51; 95% CI, 1.04–54.23). Conclusion: In the elderly, the combination uses of CYP3A4 substrate and inhibitor with 30 days or longer use of atorvastatin and fluconazole had the highest risk of rhabdomyolysis with risk factors of comorbidities of liver disease or rheumatoid disease.

참고문헌 (Reference)

1 김홍익 ; 조성호 ; 홍효림 ; 이인희 ; 안기성 ; 강건우, "졸피뎀 중독 후 발생한 횡문근융해증에 의한 급성 신손상 1예" 대한내과학회 90 (90): 550-553, 2016

2 강선우 ; 김양욱 ; 김영훈, "비외상성 횡문근융해증의 임상적 고찰" 대한내과학회 67 (67): 467-474, 2004

3 Horodinschi R-N, "Treatment with statins in elderly patients" 55 : 721-, 2019

4 Sharma RK, "The interaction between clopidogrel and proton pump inhibitors(PPI) : is there any clinical relevance" 2 : 155-162, 2010

5 Flockhart D, "The flockhart cytochrome P450 drug-drug interaction table"

6 Wongrakpanich S, "The Study of rhabdomyolysis in the elderly : an epidemiological study and single center experience" 9 : 1-7, 2018

7 Nielsen FE, "The Association between rhabdomyolysis, acute kidney injury, renal replacement therapy, and mortality" 12 : 989-995, 2020

8 PMDA, "Summary of investigation results: esomeprazole magnesium hydrate"

9 Li AP, "Substrates of human hepatic cytochrome P450 3A4" 104 : 1-8, 1995

10 Dybro AM, "Statin-associated rhabdomyolysis triggered by drug–drug interaction with itraconazole" 2016 : bcr2016216-, 2016

11 Newman CB, "Statin safety and associated adverse events : a scientific statement from the American heart association" 39 : e38-e81, 2019

12 Nandy A, "Severe rhabdomyolysis as complication of interaction between atorvastatin and fusidic acid in a patient in lifelong antibiotic prophylaxis : a dangerous combination" 2016 : 1-4, 2016

13 De Meijer AR, "Serum creatine kinase as predictor of clinical course in rhabdomyolysis : a 5-year intensive care survey" 29 : 1121-1125, 2003

14 Curfman G, "Risks of statin therapy in older adults" 177 : 966-, 2017

15 Melli G, "Rhabdomyolysis: an evaluation of 475 hospitalized patients" 84 : 377-385, 2005

16 Audrey J Lee, "Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin" 35 : 26-31, 2001

17 Hsiao SH, "Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy : a case report and literature review" 41 : 575-578, 2016

18 Nishikawa J, "Rhabdomyolysis associated with long-term treatment of esomeprazole" 115 : 299-304, 2018

19 Sauret JM, "Rhabdomyolysis" 65 : 907-912, 2002

20 Bagley WH, "Rhabdomyolysis" 2 : 210-218, 2007

21 Duncan SJ, "Proton pump inhibitors and risk of rhabdomyolysis" 40 : 61-64, 2017

22 Dresser GK, "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition" 38 : 41-57, 2000

23 Wang EC, "MR findings of alprazolam injection into the femoral artery with microembolization and rhabdomyolysis" 1 : 99-102, 2006

24 Peng F, "Exertional rhabdomyolysis in a 21-year-old healthy man resulting from lower extremity training: A case report" 98 : e16244-, 2019

25 Villeneuve J-P, "Cytochrome P450 and liver diseases" 5 : 273-282, 2004

26 Burton JR, "Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient" 41 : 133-137, 2007

27 Wollmann BM, "Associations between cytokine levels and CYP3A4phenotype in patients with rheumatoid arthritis" 46 : 1384-1389, 2018

28 Morgan TK, "A national census of medicines use : a 24-hour snapshot of Australians aged 50 years and older" 196 : 50-53, 2012